+79.4%
MRVL vs GSK
+9.8%
+69.7%
-57.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.7% | +0.5% | -5.2% | -4.5% |
| 7D | +11.0% | +1.1% | +9.9% | +11.3% |
| 30D | -36.1% | +6.3% | -42.4% | -34.8% |
| 3M | -29.4% | +1.8% | -31.2% | -28.1% |
| 6M | -11.9% | +1.7% | -13.5% | -10.9% |
| YTD | +84.8% | +6.5% | +78.2% | +85.6% |
| 1Y | +79.4% | +9.5% | +69.9% | +76.5% |
| All | +79.4% | +9.8% | +69.7% | +76.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling